Volume 11, Number 4 (May/Jun 2020)

Advanced Practitioners and the COVID-19 Pandemic

Understanding Barriers to Oral Therapy Adherence in Adults With Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a disease of older adults, with a median age at diagnosis of 68 years. The availability of oral anticancer medications has increased, although the standard treatment for AML remains in intravenous form. We...

Perceptions of Health-Care Workers of the Cost and Safety of Oral Oncolytic Agents for Patients: A Survey

Purpose: The number of newly approved cancer medications continues to grow; many of these newly approved medications are oral agents. Oral oncolytic agents have advantages including patient convenience, prolonged drug exposure, and nonin...

Risk Factors for Ifosfamide-Related Encephalopathy in Adult Cancer Patients: An Integrative Review

Patients receiving ifosfamide as part of their cancer treatment are at risk for ifosfamide-related encephalopathy (IRE), a potentially serious adverse event affecting up to 60% of patients. Symptoms range from transient altered mental st...

Waldenström Macroglobulinemia: Clinical Presentation, Diagnosis, and Management

Waldenström macroglobulinemia is a rare hematologic malignancy characterized by an IgM-associated lymphoplasmacytic lymphoma. Often, it is associated with an indolent disease course, and many patients are candidates for careful monitorin...

Mayo Clinic Hematology Fellowship for Advanced Practice Providers

Advanced practice providers (APPs), including nurse practitioners (NPs) and physician assistants (PAs), are part of a growing cancer care workforce. Current hematology-specific education provided by most graduate NP and PA school educati...

Development of a Hematology-Oncology Advanced Practice Provider Fellowship Program

New graduate advanced practice providers (APPs) who accept jobs within the hematology-oncology field face many challenges when beginning their careers. Specific challenges include a lack of specialty-specific training, expedited orientat...

Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin

The treatment paradigm for urothelial carcinoma (UC), a common genitourinary cancer, has significantly expanded in recent years. Enfortumab vedotin, a Nectin-4–targeted antibody-drug conjugate, was recently approved by the U.S. Food &...

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion

Two new targeted agents have been approved for pediatric and adult patients with advanced or metastatic solid tumors with neurotrophic receptor tyrosine kinase (NTRK) gene fusion without an acquired resistance mutation. Larotrectinib and...